CN115819406B - Synthesis method of 3- (4-pyrimidine) -1H-indole compound - Google Patents

Synthesis method of 3- (4-pyrimidine) -1H-indole compound Download PDF

Info

Publication number
CN115819406B
CN115819406B CN202310161173.0A CN202310161173A CN115819406B CN 115819406 B CN115819406 B CN 115819406B CN 202310161173 A CN202310161173 A CN 202310161173A CN 115819406 B CN115819406 B CN 115819406B
Authority
CN
China
Prior art keywords
indole
reaction
solvent
pyrimidine
lewis acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310161173.0A
Other languages
Chinese (zh)
Other versions
CN115819406A (en
Inventor
刘钢
常仁义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zibo Baiji Rongchuang Pharmaceutical Technology Co ltd
Original Assignee
Zibo Baiji Rongchuang Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zibo Baiji Rongchuang Pharmaceutical Technology Co ltd filed Critical Zibo Baiji Rongchuang Pharmaceutical Technology Co ltd
Priority to CN202310161173.0A priority Critical patent/CN115819406B/en
Publication of CN115819406A publication Critical patent/CN115819406A/en
Application granted granted Critical
Publication of CN115819406B publication Critical patent/CN115819406B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/584Recycling of catalysts

Landscapes

  • Indole Compounds (AREA)

Abstract

The invention belongs to the technical field of indole compounds, and particularly relates to a synthetic method of 3- (4-pyrimidine) -1H-indole compounds. The method comprises the following steps: adding indole and 2, 4-dichloropyrimidine into a reaction vessel, adding a Lewis acid catalyst, adding a solvent, and heating for reaction; wherein: the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride with the mol ratio of 1 (0.2-8.5). The indole is one of 5-fluoroindole, 5-methoxyindole and 5-nitroindole. The solvent is one or two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether. The 3- (4-pyrimidine) -1H-indole compound with high reaction yield is obtained by controlling the conditions of catalyst type, substrate reaction site, reaction solvent type, reaction temperature, reaction duration and the like.

Description

Synthesis method of 3- (4-pyrimidine) -1H-indole compound
Technical Field
The invention belongs to the technical field of indole compounds, and particularly relates to a synthetic method of 3- (4-pyrimidine) -1H-indole compounds.
Background
Indoles are a common and important class of organic intermediates whose structure is widely found in many natural products as well as bioactive molecules. Due to their unique molecular structure, they have been widely used in the field of functional medicines, agricultural chemicals, foods, additives, and the like in recent years. In the medical field, many natural products with good physiological activity and small molecules of drugs have indole derivative structures, such as alkaloid reserpine (reserpine), which exists in various plants of Rauvolfia, and has the effects of reducing blood pressure, slowing down heart rate and the like; the Indomethacin (Indomethacin) can be used as a medical intermediate for synthesizing antipyretic analgesic, antihypertensive drugs, vasodilators and the like, is a non-steroidal anti-inflammatory drug, has good antipyretic, anti-inflammatory and analgesic effects, and has remarkable curative effect when used for Batter syndrome; in the pesticide field, it is widely used as a high-efficiency plant growth regulator, a bactericide, etc., such as amisulbenum, which is an indole structure-containing bactericide, which has a good effect mainly on killing oomycetes and deformed fungi, and thus is widely used in the agricultural field. The 3- (4-pyrimidine) -1H-indole derivatives are compounds containing indole structures. In recent years, 3- (4-pyrimidine) -1H-indole compounds are widely applied to the research and development of medicaments due to the unique structure and good anti-inflammatory, analgesic, anti-tumor and antihypertensive activities, and are particularly embodied in the research and development of anti-tumor medicaments. If the third-generation EGFR inhibitor, namely, the oxtinib is used as a third-generation targeting drug, the EGFR 19del and L858R mutation can be inhibited, the EGFR T780M which is a first-generation EGFR targeting drug resistant mutation and a second-generation EGFR targeting drug resistant mutation can be overcome, the side effect is milder, and the adverse reaction of the oxtinib is less than 1%; SY-1365 (Mevociclib), a CDK7 inhibitor as disclosed earlier, and SY-5609, as disclosed in 2022, both showed good anti-cancer activity.
The current synthetic routes of such compounds mainly include the following three types:
the first synthetic route is a traditional synthetic route, and the synthesis of the compounds is generally carried out by adopting the thought of C-C coupling. Indole derivatives and 2, 4-dichloropyrimidine are used as raw materials, a halogen atom is introduced into the 3 rd position of indole, the halogen atom is converted into boric acid ester, and finally Suzuki coupling is carried out on the boric acid ester and the 2, 4-dichloropyrimidine, so that the 3- (4-pyrimidine) -1H-indole derivatives are obtained. The synthetic route has the defects of more reaction steps, longer reaction time, expensive palladium catalyst and the like.
The second synthetic route is to take indole derivatives and dichloropyrimidine derivatives as raw materials, and to make the indole derivatives and dichloropyrimidine derivatives in CH 3 MgBr (1 eq), indole (1 eq), tetrahydrofuran and 0-60 ℃ to produce the 3- (4-pyrimidine) -1H-indole derivative, however, the reaction yield of the synthetic route is lower.
The third synthetic route is to use indole derivatives and 2, 4-dichloropyrimidine as raw materials. Firstly, the indole derivative raw material and aluminum chloride are stirred in 1, 2-dichloroethane at 0-25 ℃ for 30min, then the temperature is raised to 55 ℃,2, 4-dichloropyrimidine is added for continuous reaction for 1.5H, and 3- (4-pyrimidine) -1H-indole derivatives are generated, wherein the reaction yield of the synthetic route is still only about 30%.
The three synthetic paths have lower reaction yields, and how to improve the synthetic reaction yields of the 3- (4-pyrimidine) -1H-indole derivatives is a problem to be solved urgently.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a synthesis method of 3- (4-pyrimidine) -1H-indole compounds, which can realize one-step reaction, shorten the steps required by the reaction, save the cost and time of the reaction, and has higher reaction yield, wherein the reaction process is shown in figure 1.
The synthesis method of the 3- (4-pyrimidine) -1H-indole compound comprises the following steps: introducing nitrogen to replace water and oxygen in a reaction vessel, then adding indole and 2, 4-dichloropyrimidine into the reaction vessel, adding a Lewis acid catalyst, adding a solvent, heating to react, controlling the TLC until the reaction is finished, adding ethyl acetate for dilution, adding purified water, carrying out liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain the 3- (4-pyrimidine) -1H-indole compound.
Wherein:
the Lewis acid catalyst is a mixture of trifluoromethanesulfonic acid and indium chloride.
The molar ratio of the trifluoromethanesulfonic acid to the indium chloride is 1 (0.2-8.5).
The indole is one of 5-fluoroindole, 5-methoxyindole and 5-nitroindole.
The solvent is one or two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether.
Preferably, the solvent is two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether, and the volume ratio of the two solvents is 1 (0.1-10).
The temperature is raised to 70-85 ℃.
The reaction time of the reaction is 1.5-2.5h.
The molar ratio of the indole to the 2, 4-dichloropyrimidine is 1 (1-5).
The molar ratio of the Lewis acid catalyst to the 2, 4-dichloropyrimidine is 1 (0.33-5.00).
The solvent is added in an amount of 10-100ml per 1mmol indole.
Compared with the prior art, the invention has the following beneficial effects:
(1) According to the invention, the trifluoro methanesulfonic acid and the indium chloride are used as Lewis acid catalysts, so that the reaction yield is greatly improved.
(2) The invention determines that the highest reaction yield can be achieved when fluorine atoms, methoxy groups and nitro groups are at the 5 th position of indole.
(3) The invention determines that the reaction yield is highest when one or two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether are used as solvents.
(4) The invention provides a synthetic method of 3- (4-pyrimidine) -1H-indole compounds, which can react indole derivatives with 2, 4-dichloropyrimidine to generate 3- (4-pyrimidine) -1H-indole compounds in one step. The synthetic method can greatly shorten the steps required by the reaction, and save the reaction cost and the reaction time.
Drawings
FIG. 1 is a reaction scheme of a synthetic pathway according to the present invention;
FIG. 2 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -5-fluoro-1H-indole prepared in example 1;
FIG. 3 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -5-methoxy-1H-indole prepared in example 2;
FIG. 4 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -5-nitro-1H-indole prepared in example 3;
FIG. 5 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -7-nitro-1H-indole prepared in comparative example 5;
FIG. 6 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -6-fluoro-1H-indole prepared in comparative example 6;
FIG. 7 is a nuclear magnetic resonance hydrogen spectrum of 3- (2-chloropyrimidin-4-yl) -7-methoxy-1H-indole prepared in comparative example 7.
Detailed Description
The present invention is further illustrated by the following examples, but the scope of the present invention is not limited thereto.
All materials used in the examples are commercially available, except as specified.
Example 1
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-fluoroindole and 0.1mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.3mmol of Lewis acid catalyst, adding 1ml of solvent, heating to 70 ℃, reacting for 1.5H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 2:1), adding 3ml of ethyl acetate for dilution, adding 3ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-fluoro-1H-indole with the yield of 77%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:0.2.
The solvent is a mixture of hexafluoroisopropanol and 1, 2-dichloroethane in a volume ratio of 1:0.1.
Mass spectrometry and nmr hydrogen spectrometry were performed on the resulting 3- (2-chloropyrimidin-4-yl) -5-fluoro-1H-indole to obtain the following results: MS (ESI) M/z calcd 247.66 (M+H), found 248.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.21 (s, 1H), 8.57 (dd,J= 18.7, 4.3 Hz, 2H), 8.13 (dd,J= 10.4, 2.7 Hz, 1H), 7.92 (d,J= 5.5 Hz, 1H), 7.53 (dd,J= 8.9, 4.7 Hz, 1H), 7.11 (td,J=9.1, 2.6 Hz, 1H). As shown in fig. 2.
Example 2
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-methoxyindole and 0.5mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.1mmol of Lewis acid catalyst, adding 10ml of solvent, heating to 85 ℃, reacting for 2.5H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 2:1), adding 30ml of ethyl acetate for dilution, adding 30ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-methoxy-1H-indole with the yield of 74%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:8.5.
The solvent is a mixture of ethylene glycol dimethyl ether and 2, 2-trifluoroethanol in a volume ratio of 1:10.
Mass spectrometry and nmr hydrogen spectrometry were performed on the obtained 3- (2-chloropyrimidin-4-yl) -5-methoxy-1H-indole to obtain the following results: MS (ESI) M/z calcd 259.69 (M+H), found 260.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.88 (s, 1H), 8.51 (d,J= 5.5 Hz, 1H), 8.39 (d,J= 3.0 Hz, 1H), 8.28 (d,J= 8.8 Hz, 1H), 7.88 (d,J= 5.5 Hz, 1H), 6.99 (d,J= 2.3 Hz, 1H), 6.88 (dd,J=8.8, 2.4 Hz, 1H), 3.81 (s, 3H). As shown in fig. 3.
Example 3
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 78%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Mass spectrometry and nmr hydrogen spectrometry were performed on the obtained 3- (2-chloropyrimidin-4-yl) -5-nitro-1H-indole to obtain the following results: MS (ESI) M/z calcd 274.66 (M+H), found 275.10. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.70 (s, 1H), 9.39 (d,J= 2.3 Hz, 1H), 8.80 (s, 1H), 8.65 (d,J= 5.4 Hz, 1H), 8.15 (dd,J= 9.0, 2.4 Hz, 1H), 8.02 (d,J= 5.4 Hz, 1H), 7.71 (d,J=9.0 Hz, 1H). As shown in fig. 4.
Example 4
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 74%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:4.
The solvent is a mixture of hexafluoroisopropanol and 1, 2-dichloroethane in a volume ratio of 1:1.
Example 5
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 77%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is a mixture of hexafluoroisopropanol and 2, 2-trifluoroethanol in a volume ratio of 1:1.
Comparative example 1
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 67%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is isopropanol.
Comparative example 2
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 61%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is dichloromethane.
Comparative example 3
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 66%.
Wherein:
the Lewis acid catalyst is ferric chloride.
The solvent is hexafluoroisopropanol.
Comparative example 4
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole, wherein the yield is 69%.
Wherein:
the Lewis acid catalyst is aluminum chloride.
The solvent is hexafluoroisopropanol.
Comparative example 5
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 7-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -7-nitro-1H-indole with the yield of 61%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Mass spectrometry and nmr hydrogen spectrometry were performed on the obtained 3- (2-chloropyrimidin-4-yl) -7-nitro-1H-indole to obtain the following results: MS (ESI) M/z calcd 274.66 (M+H), found 275.20. 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.92 (s, 1H), 8.21 – 8.02 (m, 2H),7.54 (t,J= 2.8 Hz, 1H), 7.24 (t,J= 7.9 Hz, 1H), 6.75 (dd,J=3.2, 1.9 Hz, 1H). As shown in fig. 5.
Comparative example 6
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 6-fluoroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 2:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidin-4-yl) -6-fluoro-1H-indole with the yield of 48%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Mass spectrometry and nmr hydrogen spectrometry were performed on the resulting 3- (2-chloropyrimidin-4-yl) -6-fluoro-1H-indole to obtain the following results: MS (ESI) M/z calcd 247.66 (M+H), found 248.0. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.12 (s, 1H), 8.64 – 8.50 (m, 2H), 8.42 (dd,J= 8.8, 5.6 Hz, 1H), 7.93 (d,J= 5.4 Hz, 1H), 7.30 (dd,J= 9.6, 2.4 Hz, 1H), 7.11 (ddd,J=9.8, 8.8, 2.4 Hz, 1H). As shown in fig. 6.
Comparative example 7
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 7-methoxyindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 2:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidin-4-yl) -7-methoxy-1H-indole with the yield of 38%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Mass spectrometry and nmr hydrogen spectrometry were performed on the obtained 3- (2-chloropyrimidin-4-yl) -7-methoxy-1H-indole to obtain the following results: MS (ESI) M/z calcd 259.69 (M+H), found 260.1. 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.22 (s, 1H), 8.52 (d,J= 5.5 Hz, 1H), 8.41 (d,J= 3.2 Hz, 1H), 8.01 (d,J= 8.1 Hz, 1H), 7.93 (d,J= 5.4 Hz, 1H), 7.15 (t,J= 8.0 Hz, 1H), 6.83 (d,J=7.8 Hz, 1H), 3.96 (s, 3H). As shown in fig. 7.
Comparative example 8
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 60 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 55%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Comparative example 9
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring at a rotating speed of 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 100 ℃, reacting for 2H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with a yield of 50%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Comparative example 10
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring, rotating at 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 1H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with the yield of 45%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
Comparative example 11
Introducing nitrogen to replace water and oxygen in a reaction vessel, repeating for three times, adding 0.1mmol of 5-nitroindole and 0.12mmol of 2, 4-dichloropyrimidine into the reaction vessel, starting stirring at a rotating speed of 300r/min, adding 0.04mmol of Lewis acid catalyst, adding 5ml of solvent, heating to 80 ℃, reacting for 3H, performing TLC until the reaction is finished (the volume ratio of ethyl acetate to petroleum ether is 1:1), adding 15ml of ethyl acetate for dilution, adding 15ml of purified water, performing liquid separation operation, collecting an organic phase, concentrating the organic phase, and separating by column chromatography to obtain 3- (2-chloropyrimidine-4-yl) -5-nitro-1H-indole with a yield of 59%.
Wherein:
the Lewis acid catalyst is a mixture of trifluoro methane sulfonic acid and indium chloride in a molar ratio of 1:1.
The solvent is hexafluoroisopropanol.
In summary, when the trifluoromethanesulfonic acid and the indium chloride are used as Lewis acid catalysts, and the fluorine atom, the methoxy group and the nitro group are at the 5-position of the indole, and the solvent is one or two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether, the higher yield can be achieved.

Claims (5)

1. The synthesis method of the 3- (4-pyrimidine) -1H-indole compound is characterized by comprising the following steps: adding indole and 2, 4-dichloropyrimidine into a reaction vessel, adding a Lewis acid catalyst, adding a solvent, and heating for reaction;
wherein:
the Lewis acid catalyst is a mixture of trifluoromethanesulfonic acid and indium chloride;
the molar ratio of the trifluoromethanesulfonic acid to the indium chloride is 1 (0.2-8.5);
the indole is one of 5-fluoroindole, 5-methoxyindole and 5-nitroindole;
the solvent is one or two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether;
the temperature is raised to 70-85 ℃;
the reaction time of the reaction is 1.5-2.5h.
2. The method for synthesizing 3- (4-pyrimidine) -1H-indole compounds according to claim 1, wherein the solvent is two of hexafluoroisopropanol, 1, 2-dichloroethane, 2-trifluoroethanol and ethylene glycol dimethyl ether, and the volume ratio of the two solvents is 1 (0.1-10).
3. The method for synthesizing 3- (4-pyrimidine) -1H-indole compounds according to claim 1, wherein the molar ratio of indole to 2, 4-dichloropyrimidine is 1 (1-5).
4. The method for synthesizing 3- (4-pyrimidine) -1H-indole according to claim 1, wherein the molar ratio of the Lewis acid catalyst to 2, 4-dichloropyrimidine is 1 (0.33-5.00).
5. The method for synthesizing 3- (4-pyrimidine) -1H-indole compounds according to claim 1, wherein the amount of the solvent is 10-100ml per 1mmol of indole.
CN202310161173.0A 2023-02-24 2023-02-24 Synthesis method of 3- (4-pyrimidine) -1H-indole compound Active CN115819406B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310161173.0A CN115819406B (en) 2023-02-24 2023-02-24 Synthesis method of 3- (4-pyrimidine) -1H-indole compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310161173.0A CN115819406B (en) 2023-02-24 2023-02-24 Synthesis method of 3- (4-pyrimidine) -1H-indole compound

Publications (2)

Publication Number Publication Date
CN115819406A CN115819406A (en) 2023-03-21
CN115819406B true CN115819406B (en) 2023-06-02

Family

ID=85522271

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310161173.0A Active CN115819406B (en) 2023-02-24 2023-02-24 Synthesis method of 3- (4-pyrimidine) -1H-indole compound

Country Status (1)

Country Link
CN (1) CN115819406B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995437A (en) * 2016-01-22 2017-08-01 齐鲁制药有限公司 Substituted indole or indazole pyrimidine derivatives and its production and use
AU2017295863A1 (en) * 2016-07-13 2019-02-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN111303128A (en) * 2020-04-07 2020-06-19 苏州信诺维医药科技有限公司 Polycyclic compound, preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105254615B (en) * 2014-07-11 2017-02-22 杭州华东医药集团新药研究院有限公司 Phenylaminopyrimidine derivatives and their use in preparation of drugs for resisting cancers
CN104804002B (en) * 2015-04-08 2017-02-01 河南师范大学 Synthesis method for 9H-pyrimido(4,5-b) indole compounds
IN201741031902A (en) * 2017-09-08 2019-03-15 Msn Laboratories Private Ltd
CN109134435B (en) * 2018-10-29 2023-01-03 湖南大学 Synthesis method of AZD9291
CN111574503A (en) * 2019-02-15 2020-08-25 药雅科技(上海)有限公司 Pyrimidine double aromatic ring derivative epidermal growth factor inhibitor and preparation method and application thereof
CN111909101B (en) * 2019-05-10 2022-07-19 浙江大学 EGFR kinase inhibitor and application thereof in preparation of anti-cancer drugs
CN110283162B (en) * 2019-07-09 2022-04-05 辽宁大学 Epidermal growth factor receptor inhibitor and application thereof
CN113773305B (en) * 2021-09-16 2023-08-11 中国人民解放军军事科学院军事医学研究院 Aminopyrimidine derivative and application thereof as EGFR tyrosine kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995437A (en) * 2016-01-22 2017-08-01 齐鲁制药有限公司 Substituted indole or indazole pyrimidine derivatives and its production and use
AU2017295863A1 (en) * 2016-07-13 2019-02-07 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN111303128A (en) * 2020-04-07 2020-06-19 苏州信诺维医药科技有限公司 Polycyclic compound, preparation method and application thereof

Also Published As

Publication number Publication date
CN115819406A (en) 2023-03-21

Similar Documents

Publication Publication Date Title
KR950001790B1 (en) Process for preparing 5-arylalkyl-4-alkoxy-2(5h)-furanone derivatives
CN103896954B (en) A kind of pyrazoles norcantharidin derivative and preparation method thereof and application
AU636122B2 (en) Process for the preparation of 7-substituted-hept-6-enoic and-heptanoic acids and derivatives
JPH07149723A (en) 1- amino ethyl indole derivative
NO851862L (en) PROCEDURE FOR THE PREPARATION OF NEW PYRROLOBENZIMIDAZOLES
CN108822046B (en) Method for synthesizing quinazolinone compound by one-pot method
CN116120295A (en) N-substituted imidazole formate derivative and application thereof
CN105541774B (en) 3,4- dihydrocoumarin class compounds and its preparation method and application
Pérard-Viret et al. A simple and efficient asymmetric synthesis of 3-alkyl-isoindolin-1-ones
Shi et al. Concise and divergent total synthesis of swainsonine, 7-alkyl swainsonines, and 2, 8a-diepilentiginosine via a chiral heterocyclic enaminoester intermediate
CN103554122B (en) A kind of containing chromone structure pyrazoles norcantharidin derivative and preparation method thereof and application
CN109485638B (en) Preparation method of oxitinib intermediate
Wang et al. An efficient route to quinoline-2-carboxylates via a rhodium-catalyzed oxidative [5+ 1] annulation of 2-vinylanilines with α-diazocarbonyl compounds
CN107056795B (en) A kind of loop coil hydroxyindole pentamethylene and β-lactones compound synthesis method
JPH0776209B2 (en) Process for producing optically active 3-hydroxypyrrolidine derivative
CN111808071A (en) Method for synthesizing polysubstituted aminoisoquinoline compound by cyclization of pyridine and alkyne under catalysis of rhodium
CN115819406B (en) Synthesis method of 3- (4-pyrimidine) -1H-indole compound
CA2107485C (en) Ellipticin derivatives, their preparation process and pharmaceutical compositions containing them
HU180873B (en) Process for preparing indolyl-alkyl-amine derivatives and pharmaceutical preparations containing such compounds as active substances
JPS5995266A (en) Indole derivative, manufacture of same and manufacture of beta-carboline-and tryptophane derivative
TW201028387A (en) A process for preparing quinazoline derivatives
CN104327073A (en) Semisynthetic production method of vinpocetine
EA006980B1 (en) Novel mandelate salts of substituted tetrahydrofuran derivatives
CN107805247B (en) Preparation process and application of beta-carboline compound for preparing renal fibrosis resisting medicine and/or chronic nephrosis resisting medicine
JP2006522160A (en) Process for the preparation of 2,3,5,6-substituted 3H-pyrimidin-4-one

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant